Human Genome Project. Over the past 20 years, the number of genetic disorders for which DNA testing is available has increased from about 10 to over 1,000, and the test methods have changed from reliance on linkage to DNA sequencing for recognition of mutations as small as a single nucleotide.
With new disciplines such as molecular cytogenetics, the distinction between biochemical, chromosomal and DNA test methods is becoming blurred. The variety of genetic diseases and available genetic tests presents a challenge to the full-time geneticist and is virtually incomprehensible to the average practitioner.
In 1999, the Task Force on Genetic Testing defined a genetic test as: the analysis of human DNA, RNA, chromosomes, proteins, and certain metabolites in order to detect heritable disease-related genotypes, mutations, phenotypes, or karyotypes for clinical purposes. Such purposes include predicting risk of disease, identifying carriers, establishing prenatal and clinical diagnosis or prognosis. Prenatal, newborn, and carrier screening, as well as testing in high risk families, are included. 1, 2 Although the physical examination, family history, and radiological and electrophysiological examinations appear to be excluded even when they lead to the diagnosis of genetic conditions, this definition is still extremely broad and encompasses many tests that are commonly ordered by non-geneticists (e.g., α1-antitrypsin in an emphysema patient, hemoglobin electrophoresis to rule out thalassemia trait). At the same time, the task force definition excludes paternity testing as it does not detect disease and also excludes research studies because they are not intended for clinical purposes. Most recent concerns about genetic testing have focused on DNA-based tests because of their novelty and rapid proliferation, the complexity of their interpretation, the sensitive nature of the information they reveal (e.g., paternity, risk to offspring, future disease in a currently healthy person) and their costs.
CLASSIFICATION OF GENETIC TESTING
Genetic tests can be classified according to their purpose. 1 The most obvious is diagnostic testing in which a DNA-based test is used to confirm or rule out a specific genetic disorder. Testing for Fragile-X in a boy with mental retardation is an example of diagnostic genetic testing. The second, and perhaps most controversial, type of genetic testing is predictive testing. This includes presymptomatic and predisposition testing.
In presymptomatic genetic testing, a healthy person is tested for a condition with delayed onset. A positive result indicates that the patient will develop the condition but does not indicate when this will occur. Evaluating a healthy person with a family history of Huntington's disease is an example of presymptomatic genetic testing. While there is no cure for this disease, a positive result can be used for life planning, including reproductive planning, as well as treatment.
Predisposition genetic testing differs from presymptomatic testing in that it informs individuals of an increased or decreased risk of developing the condition in question; however, the degree of certainty is unknown. This most often applies to cancer predisposition testing in which a positive result indicates a need for increased surveillance, while a negative result implies a risk similar to the general population but is not negligible. Eventually, this area could be expanded to include risk estimates for a wide range of common disorders, susceptibilities to environmental risk factors and responses to drugs and other treatments. 3 A third type of genetic testing is intended to help couples make reproductive decisions. This testing includes carrier testing, prenatal diagnostic testing and pre-implantation testing performed in conjunction with in vitro fertilization. It is very important to understand that reproductive genetic testing is not necessarily tied to abortion. When a family decides to initiate or continue a pregnancy at high-risk for a genetic condition, the information can be used for future planning, such as lifesaving treatment of the infant at birth. Other types of genetic testing not discussed in detail here include screening for newborns and for those in specific ethnic groups, as well as identity testing for paternity, zygosity and forensic purposes.
GENETIC TESTING: PANACEA OR PANDORA'S BOX?
In an ideal situation, DNA testing is less invasive, less expensive and more accurate than other test methods. A particularly striking example concerns myotonic dystrophy which, prior to DNA testing, was diagnosed by electromyography demonstrating myotonia. This test was expensive, painful and not entirely accurate since it failed to distinguish between myotonic dystrophy and other less severe myotonias and also failed to detect severe congenital cases that present with hypotonia rather than myotonia. Methods, such as muscle biopsy and creatine kinase measurement, used for the diagnosis of other muscular dystrophies are frequently inconclusive when applied to myotonic dystrophy. In the 1990s, the discovery that myotonic dystrophy results from increased repetitions of a DNA triplet on chromosome 19 led to a relatively inexpensive, non-invasive, definitive means of diagnosing myotonic dystrophy at all levels of severity ranging from subclinical to severe congenital forms of the disease.
Despite spectacular success for some diseases such as myotonic dystrophy, DNA testing is still far from becoming a universal gold standard. The reasons for caution regarding DNA testing are similar to the concerns of other laboratory tests: 1 Genetic diagnosis and testing
• Sensitivity: Although genetic testing studies the genome directly, the sensitivity is not necessarily high. Heterogeneity (i.e., the concept that more than one gene can cause a given disease) and the location of promoters or other gene-controlling elements outside the portion of the gene that is tested are the most common reasons that DNA tests fail to identify affected individuals.
• Specificity: A diagnosis is not always made by the presence of a DNA change. Some gene changes are harmless variants, and mutations in a single gene can sometimes cause several different diseases.
• Interpretation: • Cost and availability: Genetic testing is labor intensive, and laboratories may not be able to recover the costs of developing tests for rare genetic disorders. Some tests for more common disorders that do have the potential for profit have been patented. The net result is that most DNA tests are expensive and are performed by only a few laboratories. Furthermore, some tests are available only on a research basis.
The marketing of genetic tests is intensive. Not only geneticists but all practitioners and, in some instances, even the public are exposed to advertising for a wide variety of genetic tests. Laboratories tend to emphasize the number of tests available, but the practitioner may have to look elsewhere for information on test sensitivity and disease frequency. Hereditary peripheral neuropathy, also called Charcot-Marie-Tooth (CMT) disease, provides an instructive example. 4 From a genetic viewpoint, CMT is extremely complex. There are four major types that are, theoretically, distinguishable clinically or by family history. In reality, however, clinical features of CMT often overlap, and the family history may fail to provide clear evidence for any specific pattern of inheritance. Each type of CMT is divided into multiple subtypes that are recognized by a separate genetic mutation. Thus, genetic testing is important to confirm the diagnosis and to establish the pattern of inheritance.
A well-known genetic laboratory offers a "complete CMT panel" for patients with an unknown type of CMT. The informed practitioner will recognize that this panel is not truly complete, because it includes tests for only 9 of the 20 genes known to cause CMT. This understanding is vital for interpretation, because negative results on this panel do not rule out CMT. Furthermore, the tests included in the panel appear to have been chosen for their technical feasibility rather than their clinical utility. A single type, CMT1A, accounts for 40% of all CMT and is detectable by a relatively simple test that has 98% sensitivity, but the panel also includes several very rare types which account for <2% of all CMT and several tests whose specificities are low (<2%) or unknown.
The most cost-effective approach for the patient and practitioner is to start with testing for the most common type of the disease, but unfortunately marketing tends to lead the practitioner away from this common sense approach. To further complicate matters, information about available genetic testing abounds on the Internet, especially on support group websites targeted to specific diseases. Patients frequently are aware of this information and request specific genetic tests.
CLINICIAN AND TECHNICIAN INTERACTION
In order to maximize the benefits of genetic testing, it is essential to target the test to the patient. This requires an interaction between the clinician and the laboratory. The clinician must use all of the clinical information to create a differential diagnosis. Then, both the clinicians and the laboratory researchers need to work together to devise test methods for specific disorders. Lastly, the laboratory must supply an accurate interpretation of the laboratory results based on the empirical data as well as the theoretical sensitivity and specificity of the tests offered. Accurate diagnoses depend on the administration of the correct tests, which will not always be the newest or most complex. Two case vignettes concerning individuals with a "Marfanoid habitus" illustrate this concept. A patient must have involvement of three body systems with major involvement in one of them to be diagnosed with Marfan syndrome. Genetic involvement, in the sense of a fibrillin mutation or an affected first-degree relative, counts as major involvement in one system. The majority of affected patients meet the criteria based on clinical features alone or in combination with family history, but fibrillin testing can confirm the diagnosis in some borderline cases and can also be helpful for testing at-risk relatives, especially those with mild or questionable clinical features.
Case 1
A healthy infant of average length is referred for evaluation because of long fingers and a family history of Marfan syndrome. The father meets the criteria for Marfan syndrome because he has tall stature, arachnodactyly, ectopia lentis and dilated aortic root. Fibrillin testing is not necessary to confirm his diagnosis. The baby is at risk because his father is affected, but more clinical information is needed in order to confirm his diagnosis. After a slit lamp examination and echocardiogram reveal subluxed lenses and dilated aortic root, the infant is diagnosed with Marfan syndrome and is followed for possible progression of his ocular or cardiac involvement. In this instance, the echocardiogram and eye examination not only were more effective than fibrillin testing to confirm the diagnosis, but they also provided the necessary baseline clinical evaluation for treatable complications.
Case 2
A tall, very thin woman has scoliosis and arachnodactyly. She is also mentally delayed. An eye examination shows only strabismus, which is not a feature of Marfan syndrome, and her echocardiogram is normal. Because she has only skeletal involvement, she does not meet the criteria for Marfan syndrome even if she had a fibrillin gene mutation. Therefore, fibrillin testing is not indicated, but the patient still needs a diagnosis. Her cognitive deficiency is not a part of Marfan syndrome but might be a clue to the correct diagnosis. Conditions that can cause a Marfanoid habitus with mental deficiency include homocystinuria, Lujan-Fryns syndrome (unlikely in this patient because it is X-linked) and mosaic trisomy 8. 6 Further evaluation shows normal urine amino acids, but a skin biopsy confirms trisomy 8 mosaicism. Physically, it requires nothing more invasive than phlebotomy. Nevertheless, it is highly controversial, primarily because the treatment for Huntington's disease remains palliative. 7, 8 From the outset, it has been recognized that presymptomatic testing should be the patient's decision. Test results, positive or negative, can provide information that is useful for reproductive and life-planning decisions. For some individuals at risk, ending the uncertainty is paramount, but not everyone wants to know that he or she is destined to develop a fatal disease for which there is no prevention or cure. Potential adverse effects for those found to be affected are easy to imagine and include depression and possibly even suicide; loss of personal relationships; concerns about entering long-term commitments, such as education, marriage or childrearing; fear of passing the condition onto future generations; job discrimination and uninsurability. Even those found to be unaffected may suffer some unanticipated consequences, such as survivor guilt. With these concerns in mind, presymptomatic testing programs have usually involved detailed protocols, including genetic counseling and neurological and psychological evaluations, prior to testing. It is important that the results of presymptomatic testing are given during a face-to-face counseling session with a support person present for the patient.
GENETIC PREDISPOSITION:A FRAMEWORK FOR DECISIONS ABOUT TESTING
Major factors to consider regarding predisposition testing include: 
Frequency of Mutations in the Group Tested: Improving Cost-Benefit Ratios by Refining the Group

Example: Genetic Testing for Breast and Ovarian Cancer
Breast cancer is very common and affects 7% of all women by the age of 70 years. This makes breast cancer a potential target for predisposition testing, but at the same time, it poses some challenges. Although about 40% of breast cancer is familial, only about 10% can be attributed to recognizable heritable mutations. 10 Two genes, BRCA1 and BRCA2, account for approximately 85% of the identifiable genes, and due to patent issues, only a single laboratory in the United States is able to offer BRCA1/2 genetic testing at a cost of $3000 per test. This laboratory, which markets the test to all women's health care providers, has developed educational materials for geneticists, other health care providers and patients explaining the test and its possible results. 10 Nevertheless, the interpretation of the test results is complex. Positive results are usually clinically useful; however, precise recommendations for screening and prophylaxis remain controversial. With a known deleterious mutation, lifetime cancer risks can be very high (i.e., up to 87% for breast cancer and 44% for ovarian cancer) but screening, especially for ovarian cancer, is imperfect.
Prophylactic medications are still at the research stage, and even mastectomy or oophorectomy does not prevent all breast or ovarian cancers. Furthermore, up to one-third of all detectable mutations are variants of unknown significance (VUS). In order to determine if a given VUS tracks with the cancer in a family, the above-mentioned laboratory does offer free testing to certain relatives. However, physicians must interpret the test results based on the personal and family history of the patient. Negative results on BRCA genetic tests provide only limited reassurance unless there is a family member with a known mutation, and even then, it is important to recall that >90% of breast cancer cases are not due to BRCA mutations. Therefore, patients with negative results still need to follow the population screening guidelines. Even in the most reassuring situation (e.g., a patient with no history of cancer who tests negative for a known deleterious mutation found in her affected relatives), there may be complex counseling issues, such as survivor guilt. Adequate counseling prior to testing and for the interpretation of the results often requires several hours of a trained professional's time.
Clearly, with the cost of BRCA genetic tests and the need for extensive counseling in order to maximize the benefit and minimize the risks, testing of the entire female population or even all breast cancer patients is impractical. Therefore, an algorithm must be devised to identify the patients who are most likely to benefit from genetic testing. 11, 12 Families containing multiple individuals with breast and/or ovarian cancer, individuals with pre-menopausal onset of their tumors and individuals with multiple primaries are the most likely to harbor recognizable genetic changes. Many insurers, including Medicare, have already developed criteria based on the number and age of onset of affected family members. BRCA tests have also been refined with the recent addition of testing for deletions and major rearrangements rather than for just classic mutations. Additional research is also being directed at discovering other genes that contribute to hereditary breast cancer. The laboratory has published extensive educational materials for patients, families and physicians to assist in the appropriate use of the test and the interpretation of the results.
Frequency of Disease When a Mutation is Detected: Minimizing False Positives by Refining the Group
Example: Venous thromboembolism
Venous thromboembolism (VTE) is a relatively common event and is usually multifactorial. 19 which ideally would provide them with advanced warning so they could modify their lifestyle risks. However, some might conclude that if they are destined to have a heart attack anyway, they might as well continue smoking. To add to the potential feeling of hopelessness and loss of personal control, the ApoE4 allele also confers a relative risk of ≥2 for Alzheimer's disease. 20 Some individuals who become depressed upon learning that they have inherited the "bad" ApoE4 allele might choose not to even try to prevent a heart attack, because they would prefer sudden cardiac death to slowly advancing Alzheimer's disease. On the other hand, since Alzheimer's disease can occur in the absence of the ApoE4 allele, a caregiver might place too much faith in a normal ApoE result and fail to obtain services for a person with obvious clinical features of Alzheimer's disease. 21 Individuals who are counseled appropriately are more likely to recognize the risks and benefits, decline testing that is not helpful to them, and correctly understand and use results that are helpful.
CONCLUSION
Genetics is a rapidly advancing area of medicine. Over the past 50 years, new methods such as biochemical, chromosomal and, most recently, DNA-based tests have resulted in an exponential increase in the number of disorders for which genetic testing is available. Molecular genetics, however, is never going to replace clinical medicine. The history and physical examination are essential for the establishment of a differential diagnosis, which is then used as a guide for the selection of relevant genetic tests, interpretation of genetic test results, and planning of prophylaxis or therapy. Rapport with the patient is crucial in explaining the reasons for testing, the test results, the treatment plan and the implications for other family members.
